解放军医学杂志2025，Vol.50Issue(4)：387-392,6.DOI:10.11855/j.issn.0577-7402.1810.2025.0304
WHO垂体瘤新病理分类对临床无功能垂体瘤诊治的价值浅析
Value of the new WHO pathological classification of pituitary tumors in diagnosis and treatment of clinically non-functioning pituitary adenomas
摘要
Abstract
Non-functioning pituitary adenomas(NFPAs)are relatively common.Apart from hyperprolactinemia caused by pituitary compression,they typically lack overt hormonal hypersecretion and usually present with clinical symptoms due to mass effects.Previously considered a uniform entity,NFPAs are actually a highly heterogeneous group of tumors,including aggressive subtypes like silent corticotroph adenomas(SCA)and null cell adenomas.The 2022 WHO new classification of pituitary tumors employs transcription factors[e.g.,pituitary-specific transcription factor 1(PIT-1),T-box transcription factor 19(TBX19,also known as TPIT),steroidogenic factor 1(SF-1)]for detailed categorization,allowing precise subclassification of NFPAs into multiple subtypes derived from distinct cell lineages,including silent gonadotroph adenomas,SCA,and plurihormonal PIT-1-positive adenomas.This helps identify highly invasive subtypes with high recurrence risk,guiding clinical diagnosis and treatment,prognostic assessment,and individualized management.The new classification also provides a theoretical basis for targeted therapies of NFPAs(e.g.,somatostatin analogs and temozolomide).This review comprehensively discusses the latest pathological classification of NFPAs and its clinical implications,aiming to enhance understanding of this disease and offer valuable insights for precise diagnosis,treatment,and prognostic assessment.关键词
无功能垂体瘤/病理分类/转录因子/诊断/治疗Key words
non-functioning pituitary tumor/pathological classification/transcription factors/diagnosis/treatment分类
医药卫生引用本文复制引用
孙田,张雪东,郑尔涵,申浩,周涛,孟祥辉,郭清华..WHO垂体瘤新病理分类对临床无功能垂体瘤诊治的价值浅析[J].解放军医学杂志,2025,50(4):387-392,6.基金项目
This work was supported by the National Natural Science Foundation of China(82270824),the Beijing Natural Science Foundation(7232153),and the Capital Health Development Research Special Fund(2024-2-5025) 国家自然科学基金(82270824) （82270824）
北京市自然科学基金(7232153) （7232153）
首都卫生发展科研专项(2024-2-5025) （2024-2-5025）
